ClinicalTrials.gg
CompletedNCT02469519ACSinPROMUpdated Dec 15, 2022

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

A Phase 2/3 interventional study of Betamethasone - ACTIVE and Normal Saline - PLACEBO in Premature Birth, sponsored by Pediatrix. Completed at 9 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-15.

Sponsored by Pediatrix · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This trial hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity in pregnant women with pre-labor premature rupture of the membranes.

Read the detailed description

This is a multicenter randomized double blinded trial that hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity including respiratory distress syndrome in pregnant women with a singleton gestation between 24w0d - 32w6d gestation who have documented premature rupture of the membranes.

02

Conditions studied

  • Premature Birth

Browse trials for

03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's enrollment of 194 is above the median of 84 across 1,666 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Pediatrix is the lead sponsor of 34 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants age 18 years or older
  • 24w0d to 32w6d weeks gestation
  • Singleton pregnancy
  • Received first course of ACS at or prior to 31w6d gestation
  • Began first course of ACS at least 7 days ( =/> 168 hours) prior to randomization
  • Expectant management planned
  • Premature Ruptured membranes (PROM) before onset of labor

Exclusion criteria

Exclusion Criteria:

  • Known major fetal anomalies
  • Multiple gestation
  • Not a candidate for expectant management
  • Clinical chorioamnionitis (two or more of the following: temperature > 38.0 degrees centigrade; uterine tenderness; foul smelling vaginal discharge or amniotic fluid; maternal tachycardia >100 bpm; fetal tachycardia >160 bpm; maternal White Blood Cell (WBC) count >20 X 109/L; C-Reactive Protein (CRP) > 5.9
  • Already receiving for another condition
  • Any to the maternal use of corticosteroids
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Betamethasone - ACTIVE

    Booster Course of Antenatal Steroids consists of Betamethasone \[12 mg intramuscular injection, 24 hours apart X 2 doses\] or if unavailable may give Dexamethasone \[6 mg intramuscularly 12 hours apart x 4 doses\]

    Drug: Betamethasone - ACTIVE

  • Placebo comparator
    normal saline - PLACEBO

    Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.

    Other: Normal Saline - PLACEBO

Interventions

  • antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.

    Also known as: antenatal corticosteroid, dexamethasone

  • OtherNormal Saline - PLACEBO

    normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses

    Also known as: NS

06

What researchers measure

Primary outcomes

  1. Composite Neonatal Morbidity

    Composite Neonatal Morbidity includes any one or more of the following: respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or neonatal death.

    Time frame: from birth through the first 28 days of life

Secondary outcomes

  1. Gestational age of baby

    gestational age of the baby on the day of it's birth

    Time frame: measured within the first 24 hours following birth.

  2. Baby's birth weight

    weight of the baby taken with in the first hours following birth

    Time frame: measured within the first 24 hours following birth

  3. Intrauterine growth restriction (IUGR)

    a measurement done by ultrasound taken at any time during the pregnancy prior to birth

    Time frame: anytime during the pregnancy prior to birth (~ 9 months of pregnancy)

  4. Baby's Head Circumference

    a measurement of the baby's head taken within the first hours following birth

    Time frame: measured within the first 24 hours following birth

  5. Newborn Mechanical Ventilatory days

    measurement of the total number of days the baby requires mechanical ventilatory support

    Time frame: measured from birth to 28 days following birth

  6. Newborn Oxygen support days

    measurement of the total number of days the baby requires oxygen support (example: nasal cannula, CPAP)

    Time frame: measured from birth to 28 days following birth

  7. Newborn Surfactant therapy

    measurement of the need for newborn surfactant therapy within the first 28 day following birth

    Time frame: measured within the first 24 hours following birth

  8. Newborn Hospital Days

    the number of days that newborn remains in the hospital following its birth.

    Time frame: measured within the first 24 hours following birth

  9. Pneumothorax

    diagnosis of a collapsed lung supported by clinical or radiologic evidence.

    Time frame: measured within the first 24 hours following birth

  10. Maternal Infectious Morbidity

    diagnosis of maternal infection for example; chorioamnionitis, endometritis or postoperative wound infection.

    Time frame: measured within the first 24 hours following birth

  11. time from first dose of study drug to birth

    the number of hours/days from the time of the first dose of study drug until birth

    Time frame: measured in days/hours from the time of administration of first study drug until birth.

07

Study locations

9 sites
  • University of South Alabama Medical Center
    Mobile, Alabama 36617, United States
  • Phoenix Perinatal Associates
    Phoenix, Arizona 85014, United States
  • Long Beach Memorial Medical Center
    Long Beach, California 90801-1428, United States
  • Good Samaritan Hospital
    San Jose, California 95008, United States
  • Presbyterian/St Luke's Hospital
    Denver, Colorado 80218, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Lousiana State University Health Science
    Shreveport, Louisiana 60612, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • Swedish Medical Center
    Seattle, Washington 98122-4307, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Aug 2022, 77 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2015
First posted
Jun 11, 2015
StartActual
Mar 3, 2016
Primary completionActual
Aug 15, 2022
CompletionActual
Oct 31, 2022
Last update
Dec 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02469519
Lead sponsor
Pediatrix
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Mar 3, 2016
Primary completion
Aug 15, 2022
Completion
Oct 31, 2022
Last update
Dec 15, 2022

Study contacts

Richard Porreco, MD
principal investigator · Pediatrix

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion